Telix Pharmaceuticals Limited (TLX) announced a significant increase in second-quarter revenue, propelled by robust performance in its precision medicine division.
For the second quarter of fiscal 2026, the radiopharmaceutical company recorded revenue of $247 million, up from $204 million in the comparable prior-year period. Precision medicine revenue climbed to $202 million, compared to $155 million a year earlier.
Looking forward, Telix projects fiscal 2026 revenue and other income to exceed $1 billion. The company noted that revenue is tracking toward the upper end of its previous guidance range of $950 million to $970 million, supplemented by $40 million in non-refundable other income from Regeneron.
Telix also raised its fiscal 2026 research and development expenditure forecast to between $230 million and $270 million, an increase from the prior outlook of $200 million to $240 million.
In fiscal 2025, the company generated revenue of $803.8 million and invested $157.1 million in research and development activities.
Also Read
- Iran’s Interior Minister Meets PM Shehbaz in Islamabad to Discuss Ceasefire Efforts
- Miami’s cost of living now tops New York City’s despite Florida’s tax advantages
- Daulton Varsho Defends Team Effort Amid Manager’s Criticism of Blue Jays’ Offensive Energy
- Major Fire at Ukrainian Mall Following Russian Drone Attack
